Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily make copies of Novo Nordisk’s semaglutide. The gambit boosted the telehealth firm’s stock price, and executives made millions selling (...)
Site référencé: Washington Post Business
Washington Post Business
Job market probably slowed in April, as businesses braced for uncertainty
2/05/2025
Your online orders may cost more now that a tax loophole has closed
2/05/2025
Meet Kevin Warsh, the banker Trump said he preferred to run the Fed
2/05/2025
Wild stats about America’s place in the world, plus what people actually ask AI
2/05/2025
My Gen Z daughter asked if now is the time to invest as the market dips
2/05/2025
White House budget calls for $163 billion in federal cuts next year
2/05/2025
